5, 2025 /PRNewswire/ -- Novo Nordisk today announced the filing of 14 new lawsuits to safeguard patients from unsafe and unapproved compounded drugs claiming to contain "semaglutide." The defendants named in these lawsuits employ tactics that deceive patients into believing compounded products have been reviewed and approved by FDA or have equivalent safety or effectiveness as Novo Nordisk's approved semaglutide medicines
Chen Y, Li Y, Shen W, Li K, Yu L, Chen Q, et al
Tirzepatide (Zepbound), a newer dual GIP/GLP-1 receptor agonist, is also FDA-approved for weight management
Insulin should never be stopped abruptly and should only be reduced stepwise with close monitoring
Over time, that effect fades, but the appetite suppressing effects in the brain stick around